On every $100 of sales, Solventum kept about $58 after the cost of products, up from $54 a year earlier. But only $8 reached operating income, down from roughly $10. The medical-supplies company made more gross profit per dollar and less operating profit per dollar in the three months ended June 30.
The surface reading is familiar: revenue barely moved, rising 2.2% to $2.2 billion, while net income edged up 2.2% to $92 million. Diluted earnings per share rose to 53 cents from 51 cents, helped in part by a 1.1% decline in diluted shares.
The more important movement sits between gross profit and operating income. Gross margin expanded 3.8 percentage points to 58.2%, but operating income fell 15.4% to $181 million, pushing operating margin down to 8.2% from 9.9%.
Management attributed the improvement in business-segment operating margin to several items, including price, volume, savings programs, and recognition of tariff refunds. It also said tariffs, inflation, and freight partly offset those benefits.
"Business segment operating income margin increased when compared to the same period last year as benefits from price, volume, savings programs, including Transform for the Future, and recognition of receivables for IEEPA tariff refunds, partially offset by tariffs and inflation, including freight."
Solventum, Form 10-Q filed Aug. 5, 2026
That explanation makes the gross-margin gain less simple than a clean efficiency story. The company recognized receivables tied to tariff refunds and savings programs, while the consolidated operating line still declined. Solventum does not provide a single bridge showing how much of the difference came from each item.
The balance sheet adds another wrinkle. Cash fell 18.1% to $403 million. Inventory rose 8.1% to $1.0 billion, faster than sales, and accounts receivable jumped 23% to $1.3 billion. Free-cash-flow margin fell 2.6 percentage points to negative 3.1%, even though capital spending was lower year over year.
Solventum gave a separate explanation for a decrease tied to the enterprise resource planning rollout and software spending:
"The decrease was driven by the impact of higher sales in advance of the ERP deployment and higher capitalized software development costs, partially offset by additional amortization expense from the acquisition of Acera."
Solventum, Form 10-Q filed Aug. 5, 2026
The filing does not tie that sentence to every working-capital movement, so the accounting signals should not be bundled into one neat cause. The observable trade-off is narrower: stronger gross profit, weaker operating income, and less cash relative to the business's reported earnings.
Solventum's annual record provides useful context without resolving the current split. Revenue moved from $8.1 billion in 2022 to $8.3 billion in 2025, while annual operating margin moved from 20.8% to 26.2%. The business has shown that margins can move a long way without much sales growth; this three-month period shows the move need not be uniform across the income statement.
The next quarterly report's operating cash flow and accompanying receivables disclosure will provide the next factual comparison for whether the larger balance is converting into cash. For now, Solventum's arithmetic is plain enough: more gross profit per sales dollar, less operating leverage after it.